Royalty Pharma posted a 10% increase in Receipts to $925 million and a 13% rise in Royalty Receipts to $887 million in Q1, confirming strong broad-based momentum. The company’s management views the 2030 target of $4.7 billion in Portfolio Receipts as conservative given recent growth and new funding deals with Johnson & Johnson, Biogen, Merck, and Teva. Capital flexibility and share buybacks continue to support the stock, which has already returned over 100% in 2023. Investors remain optimistic about Royalty Pharma's future performance.
NextEra Energy and Dominion Energy are in talks to merge in a deal valued around $400 billion, creating one of the largest utility companies in the U.S. This merger aims to address the rapidly growing electricity demand driven by AI data centers, ind...
During President Trump's summit with Chinese President Xi Jinping, U.S. officials aboard Air Force One were instructed to discard all items received in China, including burner phones, badges, and lapel pins. This precaution addresses concerns over Ch...
MKSI Inc. reported a strong Q1 FY2026 earnings beat, with revenue rising 15% year-over-year and earnings per share up 35%, surpassing analyst expectations. Management highlighted a potential increase in wafer fab equipment (WFE) spending to $170-180 ...
US 30-year Treasury bond yields surged 18 basis points to 5.12%, reaching levels not seen since July 2007, surpassing spikes from the 2023 gilt crisis. This rise reflects a global bond market sell-off and growing concerns over the UK's government deb...
Trip.com Group is under investigation by China's State Administration for Market Regulation (SAMR) for alleged monopolistic practices, triggered by complaints from small hotel operators. This probe has led to a sharp 40% decline in Trip.com's stock p...
